EXPERIENCE OF USING THE ANTIBACTERIAL DRUG FOSFOMYCIN ESPARMA FOR THE TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN WOMEN
- Авторлар: Aboyan I.A1, Orlov Y.N1, Voloshina O.A1, Orlov N.V2, Pavlov D.S3
-
Мекемелер:
- MBUZ Clinical and diagnostic Center “Zdorovie”
- CGSEN FKUZ “Medical Unit of Ministry of Internal Affairs of MVD of Russia in Rostov Region”
- FGBOU VO Rostov State Medical University of the Ministry of Health of Russian Federation
- Шығарылым: № 4 (2019)
- Беттер: 20-25
- Бөлім: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312219
- DOI: https://doi.org/10.18565/urology.2019.4.20-25
- ID: 312219
Дәйексөз келтіру
Аннотация
Толық мәтін

Авторлар туралы
I. Aboyan
MBUZ Clinical and diagnostic Center “Zdorovie”
Email: aboyan@center-zdorovie.ru
MD, professor Rostov-on-Don, Russia
Yu. Orlov
MBUZ Clinical and diagnostic Center “Zdorovie”
Email: orlovurolog@gmail.com
urologist Rostov-on-Don, Russia
O. Voloshina
MBUZ Clinical and diagnostic Center “Zdorovie”
Email: dr_voloshina@mail.ru
Ph.D., bacteriologist, Head of the Department of bacteriological studies of centralized laboratory Rostov-on-Don, Russia
N. Orlov
CGSEN FKUZ “Medical Unit of Ministry of Internal Affairs of MVD of Russia in Rostov Region”
Email: dimm-rimm@mail.ru
epidemiologist Rostov-on-Don, Russia
D. Pavlov
FGBOU VO Rostov State Medical University of the Ministry of Health of Russian Federation5-year student Rostov-on-Don, Russia
Әдебиет тізімі
- Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653-660 doi: 10.1038/nrurol.2010.190.
- Schappert S.M., Rechtsteiner E.A. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011;(169):1-38.
- Loran O.B. Epidemiological aspects of urinary tract infections. Materials of the international symposium «Urinary tract infections in ambulatory patients». M. 1999:5-8.
- Rafalskiy V., Khodnevich L. Prevalence and risk factors of uncomplicated UTI: multicentre study sonar. Europ Urol Suppl. 2008;3(3): 267. doi: 10.1016/S1569- 9056(08)60781-2.
- Johansen T.E., Botto H., Cek M., et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents. 2011 ;38:64-70. Doi: 10.1016/j. ijantimicag.2011.09.009.
- Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13. doi: 10.1016/j.idc.2013.09.003.
- Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49:53-70. doi: 10.1067/mda.2003.7.
- Hooton T.M., Scholes D., Hughes J.P., et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335:468-474. doi: 10.1056/NEJM199608153350703.
- Scholes D., Hooton T.M., Roberts P.L., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142:20-27.
- Palagin I.S., Sukhorukova M.V., Dekhnich A.V., et al. «DARMIS» research group. Current status of antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: Results of the «DARMIS» study (2010-2011). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2012;14(4):280-302.
- Naber K.G., Schito G., Botto H., et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54:1164-1175. doi: 10.1016/j.eururo.2008.05.010.
- Czaja C.A., Scholes D., Hooton T.M., et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007;45:273-280. doi: 10.1086/519268.
- Echols R.M., Tosiello R.L., Haverstock D.C., et al. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis. 1999 29:113-119. doi: 10.1086/520138.
- Urology. Russian clinical guidelines. Ed.: Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar. 2017;501 p.
- Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21:1864. doi: 10.1016/S0149-2918(00)86734-X.
- Loran O.B. Chronic cystitis in women. Doctor. 1996;8: 6-9. Russian (Лоран О.Б. Хронический цистит у женщин. Врач. 1996;8:6-9).
- Hooton T.M. Recurrent urinary tract infection in women. Int. J. Antimicrob. Agents. 2001;17(4):259-268.
- EAU Guidelines, Urological Infections, https://uroweb.org/guideline/ urological-infections.
- Spellberg B., Guidos R., Gilbert D., et al. The Infectious Diseases Society of America The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;46:155-164 doi: 10.1086/524891.
- Alanis A.J. Resistance to Antibiotics: Are We in the Post-Antibiotic Era? Arch. Med. Res. 2005;36:697-705. doi: 10.1016/j.arcmed.2005.06.009.
- Laxminarayan R., Duse A., Wattal C., et al. Antibiotic resistance The need for global solutions. Lancet Infect. Dis. 2013;13:1057-1098. Doi: 10.1016/ S1473-3099(13)70318-9.
- World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. World Health Organization; Geneva, Switzerland: 2014.
- Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009;48:1-12. doi: 10.1086/595011.
- ECDC. EMEA. The Bacterial Challenge: Time to React. Joint Technical Report. European Centre for Disease Prevention and Control; Stockholm, Sweden: European Medicines Agency; London, UK: 2009.
- Freire-Moran L., Aronsson B., Manz C., et al. The ECDC-EMA Working Group Critical shortage of new antibiotics in development against multidrug-resistant bacteria. Time to react is now. Drug Resist. Updates. 2011;14:118-124. doi: 10.1016/j.drup.2011.02.003.
- Bergen P.J., Landersdorfer C.B., Lee H.J., et al. «Old» antibiotics for emerging multidrug-resistant bacteria. Curr. Opin. Infect. Dis. 2012;25:626-633. doi: 10.1097/QCO.0b013e328358afe5.
- Bush K., Courvalin P., Dantas G., et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 2011;9:894-896. doi: 10.1038/nrmicro2693.
- Hendlin D., Stapley E.O., Jackson M., et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166(3901):122-123.
- Popovic M., Steinort D., Pillai S., et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010;29(2):127-142. doi: 10.1007/s10096-009-0833-2.
- Skarzynski T., Mistry A., Wonacott A., et al. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure. 1996;4(12):1465- 1474. doi: 10.1016/S0969-2126(96)00153-0.
- Borisova M., Gisin J., Moyer C. Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. Microb Drug Resist. 2014;20:231-237 doi: 10.1089/mdr.2014.0036.
- Falagas M.E., Vouloumanou E.K., Samonis G., et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-347. doi: 10.1128/CMR.00068-15.
- Kastoris A.C., Rafailidis P.I., Vouloumanou E.K., et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010;66:359-368. doi: 10.1007/s00228-010-0794-5.
- Anderson G.G., Kenney T.F., Macleod D.L., et al. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/ tobramycin antibiotic combination. Pathog Dis. 2013;67:39-45. doi: 10.1111/2049-632X.12015.
- Corvec S., Furustrand Tafin U., Betrisey B., et al. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013;57: 1421-1427. Doi: 10.1128/ AAC.01718-12.
- Mihailescu R., Furustrand Tafin U., Corvec S., et al. High activity of fosfomycin and rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother. 2014;58:2547-2553. Doi: 10.1128/ AAC.02420-12.
- Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53:637-656. doi: 10.2165/00003495199753040-00007.
- Duez J.M., Mousson C., Siebor E., et al. Fosfomycin and its application in the treatment of multidrug-resistant Enterobacteriaceae infections. Clin Med Rev Ther. 2011;3:123-142. doi: 10.4137/CMRT.S5102.
- Roussos N., Karageorgopoulos D.E., Samonis G,. et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34:506-515. doi: 10.1016/j.ijantimicag.2009.08.013.
- Bergan T., Thorsteinsson S.B., Albini E. Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy. 1993;39:297-301. doi: 10.1159/000239140.
- Scaglione F., Cicchetti F., Demartini G., et al. Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt. Int J Clin Pharmacol Res. 1994;14:107-109.
- Qiao L.D., Zheng B., Chen S., et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013;3(12):e004157. doi: 10.1136/bmjopen-2013-004157.
- Michalopoulos A.S., Livaditis I.G., Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732-739. doi: 10.1016/j.ijid.2011.07.007.
Қосымша файлдар
